2036

Sun Pharma gets tentative FDA nod for generic Gleevec tablets

Sun Pharma gets tentative FDA nod for generic Gleevec tablets
PTI
Comment E-mail Print Share
First Published: Tue, Nov 17 2009. 11 43 AM IST
Updated: Tue, Nov 17 2009. 11 43 AM IST
Mumbai: Sun Pharmaceutical Industries on Tuesday said it has got tentative approval from the US drug regulator for generic Gleevec (imatinib meyslate tablets), used in the treatment of chronic myeloid leukaemia.
The US Food and Drug Administration (USFDA) has granted tentative approval for the company’s abbreviated new drug application (ANDA) for generic Gleevec, Sun Pharma said in a filing to the Bombay Stock Exchange (BSE).
The tentatively approved drug (imatinib meyslate tablets) is therapeutically equivalent to Gleevec tablets of Novartis.
The approval of imatinib mesylate tablets are in the strengths of 100 mg and 400 mg.
The annual sales of these tablets are about $950 million in the US.
Shares of Sun Pharmaceutical were trading at Rs1,451.90, down 1.74% in the morning trade on the BSE.
Comment E-mail Print Share
First Published: Tue, Nov 17 2009. 11 43 AM IST
blog comments powered by Disqus
  • Wed, Jul 23 2014. 06 06 PM
  • Wed, Jul 16 2014. 06 10 PM
ALSO READ close

Sun Pharma recalls 200 vials of cancer drug: FDA

Subscribe |  Contact Us  |  mint Code  |  Privacy policy  |  Terms of Use  |  Advertising  |  Mint Apps  |  About HT Media  |  Jobs
Contact Us
Copyright © 2014 HT Media All Rights Reserved